Literature DB >> 3517786

[A new agglutination reaction for the diagnosis of the developmental stage of acquired toxoplasmosis].

P Thulliez, J S Remington, F Santoro, G Ovlaque, S Sharma, G Desmonts.   

Abstract

Agglutination of acetone treated toxoplasma (AC) is different from that one of formalin fixed parasites (HS). Sera from patients with a recently acquired ("acute") infection agglutinate both HS and AC parasites suspensions as well; contrary to sera from patients with past infection ("chronic stage") in which high titers of HS agglutination are often present, while the titres of AC agglutination are lower even negative. This is markedly observed in patients with local lesions (relapsing chorioretinitis, patients with AIDS and brain abscesses). The reason might be that different membrane toxoplasma antigens may induce the synthesis of agglutinating IgG. For example, antigens 35 KD and 27 KD described by E. Handman et al. The antibody specific for 27 KD is apparently present mainly during acute infection, contrary to the antibody specific for 35 KD which might be responsible of the high HS agglutination titre in sera from patients with chronic infection. Even if these hypotheses were not confirmed in the future, comparison of the titre in the HS and AC agglutination test might actually be helpful for practical diagnosis of the stage of toxoplasma infection.

Entities:  

Mesh:

Year:  1986        PMID: 3517786

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  13 in total

1.  Importance of membrane-bound antigens of Toxoplasma gondii and their fixation for serodiagnosis of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome.

Authors:  Y Suzuki; J S Remington
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

2.  Performance of European laboratories testing serum samples for Toxoplasma gondii.

Authors:  J C Petithory; I Reiter-Owona; F Berthelot; M Milgram; J De Loye; E Petersen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

3.  The infection-stage-related IgG response to Toxoplasma gondii studied by immunoblotting.

Authors:  C Verhofstede; P Van Gelder; M Rabaey
Journal:  Parasitol Res       Date:  1988       Impact factor: 2.289

4.  Differential agglutination test for diagnosis of recently acquired infection with Toxoplasma gondii.

Authors:  B R Dannemann; W C Vaughan; P Thulliez; J S Remington
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

5.  Kinetics and time dependence of the differential agglutination of acetone [AC]- and formalin [HS]-fixed Toxoplasma tachyzoites by serum of mice with experimental toxoplasmosis.

Authors:  Nehad Mahmoud Ali; Khaled Sayed Mohamed Habib
Journal:  J Parasit Dis       Date:  2012-01-20

6.  Use of acute-stage-specific antigens of Toxoplasma gondii for serodiagnosis of acute toxoplasmosis.

Authors:  Y Suzuki; P Thulliez; J S Remington
Journal:  J Clin Microbiol       Date:  1990-08       Impact factor: 5.948

7.  Spiramycin treatment of Toxoplasma gondii infection in pregnant women impairs the production and the avidity maturation of T. gondii-specific immunoglobulin G antibodies.

Authors:  V Meroni; F Genco; C Tinelli; P Lanzarini; L Bollani; M Stronati; E Petersen
Journal:  Clin Vaccine Immunol       Date:  2009-08-19

8.  Toxoplasma gondii seroprevalence in Mali.

Authors:  Dinkorma T Ouologuem; Abdoulaye A Djimdé; Nouhoum Diallo; Ogobara K Doumbo; David S Roos
Journal:  J Parasitol       Date:  2012-08-27       Impact factor: 1.276

9.  Antigen(s) responsible for immunoglobulin G responses specific for the acute stage of Toxoplasma infection in humans.

Authors:  Y Suzuki; P Thulliez; G Desmonts; J S Remington
Journal:  J Clin Microbiol       Date:  1988-05       Impact factor: 5.948

10.  Diagnosis of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome by using a new serologic method.

Authors:  Y Suzuki; D M Israelski; B R Dannemann; P Stepick-Biek; P Thulliez; J S Remington
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.